Baszucki Group

Baszucki Group is driven by bold, new ways of thinking. We are inspired by Meru Health's vision for improving mental health care and their focus on the important connection between mental, physical and metabolic health. We are proud to support their mission and look forward to seeing how their journey evolves.

Baszucki Group is hosting a workshop at #SIRS2026 highlighting emerging metabolic psychiatry approaches for schizophrenia. We’ll share insights from recent pilot trials, discuss real-world implementation, and hear from a lived experience perspective energized by new hope for treatment options. Join our panelists @ShebaniMD @ErinLBellamy @ProfDeannaK, Wednesday, March 25 at 3:30 CET in Room Verde!

To learn more about the clinical evidence discussed in this article and additional published research, visit @Metabolic_Mind's Foundational Clinical Trials page: metabolicmind.org/resources/scie…

A piece published today by @nytimes is an exciting example of how the emerging field of metabolic psychiatry is gaining national attention. This story highlights key Baszucki Group-funded research from @StanfordMed, @OhioState, and @EdinburghUni. 🔗 nyti.ms/4sj2WZD Baszucki Group remains committed to advancing this mission, and we look forward to important new studies, including two RCTs, that have been completed with results to be shared in the coming months. More investment in research and clinical adoption is needed, eventually on a scale that will require public funding. We look forward to following the evidence as it emerges, and we applaud the great work of the researchers, clinicians and the people with lived experience who have helped to chart this path forward.

Can a keto diet "cure" serious mental illness? Here's my piece published today in @sfchronicle. "OPINION: Diagnosed with bipolar disorder, my son began a medically supervised ketogenic regimen — and it sent his symptoms into lasting remission, Jan Ellison Baszucki writes." To read the full oped, just enter your email when prompted for the gift link: tinyurl.com/3kwrcxyu In response to comments from HHS Secretary, Robert F. Kennedy Jr., I share our family's story about how after half a decade of illness, ketogenic therapy has kept my son's bipolar I disorder symptoms in remission since 2021. I include the latest on the emerging science and practice of this therapeutic approach. "Has my son been 'cured'? It’s not a term we use in our work, and it’s also not the most important question. The more pressing concern is whether we are willing to rigorously test promising new treatment approaches when conventional care has failed far too many." @Metabolic_Mind @ChrisPalmerMD @BaszuckiGroup @matthewbaszucki @DavidBaszucki @metcoalition @LWSchizophrenia

Last year, Baszucki Group announced the inaugural recipients of the Metabolic Psychiatry Scholar Award. We’ve since expanded each scholar’s profile to include additional details on their specific research and clinical focus areas. We look forward to following the progress of these important projects. Learn more about the awardees and their areas of focus by visiting their individual profiles: bit.ly/4kHv71m

Baszucki Group is excited to invest in Neurovitals, which employs metabolic science, neuroscience, and real-time generative AI in a way that empowers users to improve mental well-being. Their leadership team is committed to data-driven approaches that will help to improve lives and lower the barrier to effective treatment. Learn more: neurovitalsai.com

With the holidays and end of year approaching, we wanted to share a look back at the work we did in 2025. The field of metabolic psychiatry continues to blossom around the globe! Generating evidence is necessary to impact clinical care. This year, two additional foundational pilot trials were published - a bipolar trial from @EdinburghUni and a trial in college students with depression from @OhioState. Three additional trials completed and will hopefully be published soon - an anorexia nervosa pilot trial, and two randomized controlled trials in bipolar and schizophrenia. As we build upon this foundational evidence for the use of ketogenic therapy in serious mental illness, newly funded work will aim to fill gaps in our current body of knowledge. Research has begun in youth, early psychosis, and low resource communities. As the evidence continues to grow, we endeavor to help build clinical capacity to meet the growing demand by peers and families. In the last year, we took on the task of helping to create continuing medical education that is provided free to healthcare providers. Nearly 6000 healthcare providers participated in these new courses this year, covering topics such as “The Evidence Supporting Ketogenic Therapy for the Treatment of Serious Mental Illness”, “Managing Major Mental Illness with Dietary Change: The New Science of Hope”, and “Cardiovascular Safety of Ketogenic Therapy”. Additionally, we recognized the need to connect clinicians around the world as they begin to learn about metabolic psychiatry. In November, we launched a survey to build a new community of practice for all types of clinicians. In just one month, over 350 people responded with interest, and this community will be a focus of our efforts in 2026 as we begin to realize what the community needs most. We also made four impact investments to build capacity and drive innovation in the field of metabolic psychiatry, including two digital health companies that support metabolic psychiatry, a technology company creating novel enzymes to measure and monitor ketosis, and a neuro-modulation company aiming to restore the brain’s metabolic health. The final pillar of our work in 2025 was the continued growth of partnerships with professional societies and advocacy groups. We are continuing to build relationships with professional organizations in bipolar disorder, schizophrenia, and the broader field of psychiatry, attending and speaking at their annual meetings and providing support for their programs and communities. The advocacy community has also begun to express interest in metabolic psychiatry, with new partnerships with @BipolarUK, @BipolarScotland, and the National Alliance on Mental Illness. We are grateful for all of our partners who continue to work towards a world in which metabolic therapies are accepted and available in clinical practice!

How amazing to see the recipient of our first and so far only $1.5 million Baszucki Prize in Science, Dr. Martin Picard @MitoPsychoBio, appear on @hubermanlab. metabolicmind.org/resources/news… Dr. Picard is not only pioneering the field of mitochondrial psychobiology, he has conceived a new model for biomedicine centered on energy as the missing dimension of health. This might just be the most important guest Huberman has ever hosted in the service of transforming how we conceive, study and protect health and vitality for generations to come.

Cleveland Clinic Neurological Institute and Baszucki Group Team Up to Advance Landmark Brain Study with Metabolic Health Markers: The collaboration seeks to study gut-brain connections in neurological disorders. Baszucki Group today announced an expanded commitment to the landmark @ClevelandClinic Brain Study. Launched in 2022, this ambitious longitudinal study plans to follow healthy individuals over a 20-year period with the goal of identifying early disease markers and therapeutic targets needed to prevent and ultimately cure neurological diseases. The commitment from Baszucki Group brings their total donation to the study to $450,000. Baszucki Group’s support has expanded the scope of the Cleveland Clinic Brain Study to include biomarkers from stool samples–a key assessment that could reveal the relationship between the gut and brain and how this connection influences disease risk. This data will help researchers explore how metabolic health relates to brain function, an area of priority for Baszucki Group. “By including these additional assessments, the Brain Study is taking a critical step towards understanding the brain within the context of the whole body,” said @janellison, co-founder and president of Baszucki Group. “This broad, holistic approach to data gathering is key, as it maximizes the possibility of revealing the underlying factors that contribute to neurological dysfunction and uncovering potential treatment options.” Learn more or enroll in the study: cle.clinic/4rHltyF Read the full press release: bwnews.pr/4pvFoiF

Baszucki Group is proud to announce a partnership with @UMmedschool for an innovative training initiative that will build capacity for delivering ketogenic metabolic therapy in mental health care. Led by @ProfDeannaK, this initiative aims to educate and empower practitioners by guiding them in adopting the intervention themselves. The aim is to prepare a variety of healthcare professionals to safely and confidently incorporate this promising personalized metabolic treatment framework in both clinical and research settings. This program is part of a continued commitment by Baszucki Group to expand access to metabolic therapies for patients with serious mental illness by supporting key research and capacity-building projects. “Our hope is that the information gathered from this model will be used to shape the future development and expansion of similar programs globally,” said Julie Milder, PhD, Director of Neuroscience at Baszucki Group. Read the full press release: bwnews.pr/4pNrfNu

Baszucki Group is bringing together clinicians to build a metabolic psychiatry community of practice. Our goal is to connect clinicians, share knowledge, and expand access to ketogenic metabolic therapies for mental health care. By supporting this growing network, we hope to increase the number of clinicians worldwide who are equipped to deliver ketogenic metabolic therapies safely and effectively. If you’re a clinician working in or interested in metabolic psychiatry, we’d love to hear your perspective. 👉 Please take a few minutes to complete our brief survey: bit.ly/4r6b8fI #MetabolicPsychiatry #MentalHealth #KetogenicTherapy

Tomorrow, @bschermd will be joining a roundtable discussion at The Behavioral Health Tech Conference titled: Radical Rethink: Serious Mental Illness Care That Works The panel will explore innovative strategies to integrate behavioral health, primary care, social services, and digital platforms to deliver high-quality care for individuals living with serious mental illnesses. Key Takeaways: ✅What effective, modern SMI care looks like and how it improves on traditional models. ✅Strategies to integrate care, enhance access, and leverage digital tools to engage patients and improve outcomes. ✅Approaches to addressing workforce challenges, clinician burnout, and operational barriers while driving measurable impact. 👇To learn more about the role of metabolic psychiatry in this conversation, visit the link in the first comment and read the article @BaszuckiGroup president @janellison wrote for @GoingDigitalBHT.

Baszucki Group is proud to announce the six recipients of the first-ever Metabolic Psychiatry Scholar Award. This new initiative supports exceptional early-career scientists and clinicians working to advance understanding of the connection between metabolic health and mental health. The six scholars will each receive up to $150,000 over 18 months for original research in metabolic psychiatry. The award program advances Baszucki Group’s mission to transform mental health outcomes through research at the intersection of metabolism, psychiatry, and neuroscience. Scholars will also receive mentorship, professional development, and communication support to amplify the impact of their research. The scholars’ work falls broadly into two subcategories: research and clinical capacity-building. Four of the awardees are engaged in translational and clinical research into the links between metabolic health and mental health: Jacek Kolacz, PhD (@jacek_kolacz), Eline Dekeyster, PhD, Sean Nestor, MD, PhD, and Gabriel Fries, MSc, PhD (@FriesGabriel). Two of the awards will support clinical capacity-building projects aimed at expanding support for ketogenic therapy across the UK and Canada. These projects are led by Fabiano Alves Gomes, MD, MSc, PhD (@fagomes1981), and Erin Bellamy, PhD (@erinlbellamy). “The strength of the candidates who applied to this open call highlights the global enthusiasm to explore metabolic psychiatry's potential,” said Julie Milder, PhD, Director of Neuroscience at Baszucki Group. “From foundational research to clinical capacity building, their work has the potential to revolutionize patient treatment. We anticipate that this award marks the start of a lasting initiative that will continue to support the field for years to come.” Read the press release: bit.ly/4hs7bO0 Learn about each awardee: bit.ly/3Wh7rWk

Baszucki Group is proud to support @AccordMetabolic and @McLeanHospital as they lead a groundbreaking study on metabolic psychiatry. bit.ly/4nCeu7E With $600,000 in funding from Baszucki Group, this research will explore the metabolic basis of psychiatric conditions and identify the biomarkers that can be tracked to guide treatment and recovery. This work is a vital step toward advancing our understanding of the metabolic roots of psychiatric conditions and shaping new standards of care in mental health. We are honored to help make this research possible, supporting efforts that could transform how mental illness is understood and treated in the years to come. Learn more by reading Accord's press release: bit.ly/4nCeu7E

Congratulations to the team @OhioState who have today published the results of a pilot study on ketogenic diet for depression in college students in @Transl_Psych. We were honored to fund this research study, which found that 16 college students with major depressive disorder experienced significant improvements in symptoms and overall well-being after 10-12 weeks of ketogenic therapy. Led by Jeff Volek, PhD, RD, Professor in the Department of Human Sciences, the study found that depressive symptoms decreased by an impressive 69%-71% across depression scales over the course of the trial. Read the paper here: doi.org/10.1038/s41398…

For four years, my husband, @DavidBaszucki, and I have dedicated resources to advancing metabolic therapies for mental health, like the kind that helped our son, @BaszuckiMatt, recover from a serious illness. During this time, we worked hard to stay in our lane and remain focused on mental health. I vowed not to dilute our efforts by taking on too much. But sometimes, taking on too much is the only reasonable path. The body and brain are not separate. Americans are facing both a mental and physical health disaster, and we feel compelled to step up to take on this larger challenge. Today, our family is committing $50M to combat America's broader health crisis. The launch of @metcoalition, the Coalition for Metabolic Health, represents our commitment to reversing the chronic disease burden of America's adults and children. We vow, today, to do our part to make the next generation of Americans the healthiest in history, and we believe this goal is within reach. We are honored to bring together experts who have been fighting for decades to bring metabolic health to the mainstream. We are in their debt for their tireless efforts, which we are now dedicating ourselves to supporting and amplifying. Join us in this mission by following CMH on social channels and sharing this announcement. We have nothing if we do not have our health, and we are all in this fight together. @Metabolic_Mind @BaszuckiGroup @bschermd

Today, our founders @janellison and @DavidBaszucki launched the @metcoalition -- an alliance of scientists, clinicians, and advocates working to put metabolic health at the center of America's fight against chronic disease. Learn more at coalitionformetabolichealth.org

🗓️Mark your calendar! We may be a little biased, but you don’t want to miss this opportunity to hear from @baszuckigroup’s Director of Neuroscience, Dr. Julie Milder, on the evidence for ketogenic therapy in bipolar treatment. Dr. Milder, whose PhD research focused on the effects of the ketogenic diet on mitochondrial function, brings extensive experience and expertise in ketogenic therapy and pediatric epilepsy—expertise that has been instrumental in advancing the groundbreaking research being funded by Baszucki Group. 👇Visit the post below to register for the event!

We honored Dr. Martin Picard's work @MitoPsychoBio with the $1.5M Baszucki Prize in Science last year. scientificamerican.com/article/why-mi… We could not be more proud of the progress he and his lab are making to help us understand how mitochondrial health drives human health. This new article in Scientific American is a must-read.